Jana SFB's more recent Q4 FY26 numbers complicate the Q3 profit-collapse narrative, without resolving it Banks
JSFB's Q4 FY26 investor presentation shows PAT of Rs 140 crore (in line with guidance), 23% YoY growth in assets and deposits, GNPA down to 2.3% and declining net credit cost, with the bank shifting its mix away from microfinance (now ~27% of the book, from 40% in March 2024). That's in tension with the Q3 FY26 collapse (-90.6% YoY profit, 16.6% JLG bad-loan ratio) underlying the open ledger claim, though full-year FY26 profit is still down 34.9% YoY and the sourcing is second-hand rather than a fetched transcript — this nudges, but doesn't resolve, the deterioration thesis.
Lupin's US business grew fast last quarter, but management still guides the run-rate down as generic competition bites Pharmaceuticals
Coverage of Lupin's most recent US quarter shows sales up 47% YoY on continued Tolvaptan exclusivity and new launches, yet management holds its guide toward $250-280M in quarterly US sales (down from Q1's $366M) as Apotex, Teva and a possible fourth generic entrant erode pricing, with recovery still pointed at FY28. Two evidence sources gave the growth figure as '$315M, Q2 FY27' and '$366M, Q1' for what reads like the same underlying trend — a discrepancy worth a primary-source check before it drives a score. Either way, this reinforces rather than resolves the open trough claim.
Infosys formalizes its second FY27 guidance cut; HCLTech's guidance stays exactly where it was Information Technology
Infosys trimmed FY27 constant-currency revenue guidance to 1.5-3.0% (from 1.5-3.5%) at its Q1 results, citing softer volumes, a one-time client contract termination and macro uncertainty, even as deal TCV came in strong ($3.6bn, 61% net new). HCLTech's own 1.0-4.0% FY27 guide, set at its Q4 FY26 results, has seen no revision either way. Both continue, rather than change, the pattern the open claim already tracks: strong order books across large-cap IT, but nobody raising.
The NCLT case against Max Healthcare's newly acquired Kalinga Hospital drags into a third adjournment Healthcare & Hospitals
BRS Capital Two's oppression/mismanagement petition against Kalinga Hospital — the Bhubaneswar hospital Max Healthcare bought a 58.28% controlling stake in for ~Rs 298 crore in May 2026 — was adjourned again on Aug 19, to Sept 8, with BRS Capital's own counsel seeking the delay this time. An interlocutory petition inside the case is specifically trying to block a postal ballot that would raise the hospital's borrowing limits, so the unresolved dispute could constrain KHL's own ability to fund its expansion while it drags on.